Infliximab for severe, treatment resistant psoriasis: a prospective, open-label study

被引：0
|
作者：
Smith, CH [1 ]
Jackson, K [1 ]
Bashir, S [1 ]
Chew, A [1 ]
Powell, A [1 ]
Perez, A [1 ]
Wain, M [1 ]
Barker, JNWN [1 ]
机构：
[1] St Thomas Hosp, St Johns Inst Dermatol, London, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2006年 / 154卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study
    Smith, C. H.
    Jackson, K.
    Bashir, S. J.
    Perez, A.
    Chew, A. L.
    Powell, A. M.
    Wain, M.
    Barker, J. N. W. N.
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (01) : 160 - 169
  • [2] Fumaric-acid esters (Fumaderm®) for severe, treatment resistant psoriasis:: a prospective, open-label study
    Smith, CH
    Jones, E
    Wain, M
    Barker, JNWN
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (01)
  • [3] Open-label study of alefacept in the treatment of palmoplandar psoriasis
    Pearce, D
    Feldman, S
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (01) : A7 - A7
  • [4] Tacrolimus in the treatment of severe chronic idiopathic urticaria: An open-label prospective study
    Kessel, A
    Bamberger, E
    Toubi, E
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (01) : 145 - 148
  • [5] Interim results from an open-label extension study of briakinumab for the treatment of moderate to severe psoriasis
    Langley, Richard G.
    Williams, David
    Papp, Kim
    Olds, Michele
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB195 - AB195
  • [6] Treatment of nail psoriasis with brodalumab: an open-label unblinded study
    Gregoriou, S.
    Tsiogka, A.
    Tsimbidakis, A.
    Nicolaidou, E.
    Kontochristopoulos, G.
    Rigopoulos, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (04) : E299 - E301
  • [7] Experience with infliximab for severe treatment-resistant psoriasis
    Smith, C
    Jackson, K
    Powell, A
    Barker, J
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 : 54 - 55
  • [8] INFLIXIMAB IS AN EFFECTIVE GLUCOCORTICOID-SPARING TREATMENT FOR TAKAYASU ARTERITIS: RESULTS OF A MULTICENTER OPEN-LABEL PROSPECTIVE STUDY
    Mertz, P.
    Kleinmann, J. F.
    Lambert, M.
    Puechal, X.
    Martin, T.
    Sibilia, J.
    Arnaud, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1548 - 1549
  • [9] Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study
    Mertz, Philippe
    Kleinmann, Jean-Francois
    Lambert, Marc
    Puechal, Xavier
    Bonnin, Anthony
    Boulon, Carine
    Diot, Elisabeth
    Hachulla, Eric
    Harid, Naoual
    Harle, Jean-Robert
    Helder, Gil
    Kahn, Jean-Emmanuel
    Kone-Paut, Isabelle
    Lavigne, Christian
    Magy-Bertrand, Nadine
    Maillard, Helene
    Martin, Thierry
    Maurier, Francois
    Poindron, Vincent
    Schleinitz, Nicolas
    Sibilia, Jean
    Arnaud, Laurent
    AUTOIMMUNITY REVIEWS, 2020, 19 (10)
  • [10] Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO)
    Ayala, Fabio
    Lambert, Julien
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2015, 26 (04) : 304 - 311
12345